DOCSLIB.ORG

Corporate Presentation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corporate Presentation Nanobodies® creating better medicines Corporate presentation February 2017 Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company or, as appropriate, the Company directors’current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. 2 2 Ablynx Rapid growth since its foundation in 2001 Today R&D – late stage 2007 o > €370M in equity and debt R&D – early stage o > €400M cash from partners o > 45 R&D projects o €70M private equity o > 1,500 patients treated o €85M IPO (Euronext) o 8 Nanobodies in the clinic 2002 o 11 R&D projects st Technology platform o 1 Nanobody expected to be o 1 Nanobody in the clinic launched in 2018 o €5M seed financing o 3 partners o 8 partners o No products o 144 employees o ~ 400 employees o No partnerships st o €235M in cash at 31 Dec 2016 o 10 employees 2001 Foundation Evolving into a commercial stage biotech company 3 3 Broad product pipeline >45 programmes, 8 Nanobodies in clinical development Product Indication Target Pre-clinical Phase I Phase II Phase III Filing caplacizumab aTTP vWF vobarilizumab RA IL-6R SLE IL-6R + ALX-0171 RSV RSV Up to 17 Immuno-Oncology Various programmes ozoralizumab RA TNFα Japan RA TNFα Greater China ALX-0761/M1095 Psoriasis IL-17A/IL-17F BI 836880 Oncology VEGF/Ang2 BI 655088 Chronic kidney disease CX3CR1 NA Inflammation CXCR2 ALX-0141 Bone disorders RANKL Greater China >15 wholly- owned and Various partnered programmes Filing in EU based on Phase II TITAN data 4 Four key pillars of value First marketed product expected 2018 Caplacizumab ALX-0171 Vobarilizumab Immuno- (anti-vWF) (anti-RSV) (anti-IL-6R) oncology • First-in-class treatment for • Potential breakthrough • Novel potential best-in- • Up to 17 programmes acquired thrombotic treatment delivered by class treatment for partnered with Merck & thrombocytopenic purpura inhalation for respiratory rheumatoid arthritis (RA); Co in deal worth up to • Acute, life threatening, syncytial virus infections also being studied in €5.7Bn in milestones plus ultra-rare blood clotting (RSV) systemic lupus royalties disorder • RSV can be very serious erythematosus (SLE) • First in vivo pre-clinical • No indicated therapeutic in infants, the elderly and • Partnership with AbbVie milestone achieved drug currently available the immune-compromised • RA - two successful • First clinical studies • Filed for approval in • No approved therapeutic Phase IIb studies; planned for 2017 Europe in H1 2017 drug currently available preparing for regulatory • Up to 9 clinical studies meetings and potential • Phase III results expected • Phase IIb topline results expected to start over expected in H2 2018 Phase III; exploring new next three years in H2 2017; potential BLA partnership options filing in H1 2018 • Multi-billion $ market • Market expected to grow • SLE – Phase II topline to >$43bn by 2020 • Wholly-owned; potentially • Wholly-owned results expected in H1 Ablynx’s first marketed 2018 product in 2018 • Large, multi-billion $ • Self-commercialisation markets strategy being executed • Peak sales potential of > €400M 5 Key events in 2016 Significant progress across the entire business Study results Pipeline development Corporate • ALX-0171 (anti-RSV): excellent • Bi-specific anti-VEGF/Ang2: Phase I • Caplacizumab (anti-vWF): safety and encouraging efficacy start by BI - €8M milestone publication of Phase II data from in Phase I/IIa study (53 TITAN study in the NEJM hospitalised infants with a RSV • Anti-CX3CR1 (GPCR): Phase I start infection) by BI - €8M milestone • Caplacizumab (anti-vWF): announced commitment to self- • Vobarilizumab (anti-IL-6R): • Anti-CXCR2 (GPCR): Phase I start by Novartis commercialize in North America excellent safety and superior and Europe efficacy versus tocilizumab in • Caplacizumab (anti-vWF): start of 3- • Financing: successfully raised Phase IIb RA monotherapy study year follow-up study for patients (251 RA patients) completing the Phase III HERCULES €74M through oversubscribed private placement of new shares • Vobarilizumab (anti-IL-6R): study excellent safety and efficacy in • Merck & Co., Inc.: extension (for • Vobarilizumab (anti-IL-6R): nd Phase IIb RA combination Completed recruitment of 300 patients the 2 time) of ion channel (+MTX) study (345 RA patients) in Phase II SLE study collaboration - €1M payment • Caplacizumab (anti-vWF): >100 • Novo Nordisk: discovery patients already recruited in Phase III milestone with multi-specific HERCULES study Nanobody - €1M milestone • AbbVie: declined to opt-in and license vobarilizumab in RA 3 successful studies in a 4 clinical trial starts, 3 of Important corporate total of ~650 patients which were with partners developments 6 Ablynx Diversified shareholder base – January 2017 • Ordinary shares listed on Euronext Brussels (ABLX) • Sponsored Level I ADRs on the US OTC market (ABYLY) • 61.1M shares outstanding • 2.5M outstanding warrants (in number of shares) Breakdown of share capital % of Institutional Shareholders by Geography (representing 87% of total S/O) France Van Herk Investments B.V. (NL) 2% 10% Other Scandinavia 4% Fidelity Management Research 1% 9% LLC (FMR LLC) (US) The Bank of America (US) Netherlands 14% US 5% 38% Perceptive Advisors (US) 5% GAM International (UK) 4% 64% Belgium 3% Boehringer Ingelheim (DE) 21% Other shareholders UK 20% 7 Nanobodies Derived from heavy-chain only antibodies • Camelid heavy-chain only antibodies are stable and fully functional • Nanobodies represent the next generation of antibody-derived biologics V H 12-15kDa VHH CH1 VHH VL Ablynx’s Nanobody • small and robust CL CH2 • easily linked together CH2 • sequence homology comparable to humanised/human mAbs CH3 CH3 • nano- to picomolar affinities • able to bind and block challenging targets Conventional Heavy chain only • multiple administration routes antibodies antibodies • manufactured in microbial cells 8 Ablynx’s Nanobody drug discovery engine Rapid generation of novel biologics Immunise llamas with antigen and/or Wide range of highly Formatted Cloned into microbial diverse Nanobodies with Use proprietary synthetic Nanobodies systems and produced 0.1-10nM affinities Nanobody phage libraries through fermentation ~12-18 months 9 Ablynx’s Nanobodies Platform advantages Mix and match Multiple delivery routes Multi-specific/multivalent Nanobodies that address multiple targets in a single drug molecule – flexible GS linker lengths Inhalation Ocular Oral-to-topical Able to bind and block Manufacturing challenging targets Customised half-life extension High-yield, high- Hours/days/weeks concentration, Nanobodies low-viscosity, against ion Albumin- microbial channels and binding production GPCRs Nanobody Fc 10 Key value drivers Ablynx SOTP valuation – analyst average • Average target price: €15/share • Average target equity value: €880M* • Average value per programme: €29M €106M Cash minus costs Other 3% partnerships €59M 12% Merck IO 7% caplacizumab 50% €439M ALX-0171 15% €128M vobarilizumab 13% €117M *Current number of outstanding shares: 60.9M 12 Caplacizumab (anti-vWF) – wholly-owned Potential first-in-class treatment of acquired thrombotic thrombocytopenic purpura (aTTP) Caplacizumab – anti-vWF Nanobody First-in-class potential for the treatment of aTTP • Total annual market potential ~€800M1 • Feb 2017: filed in Europe for approval • Phase III HERCULES topline results in H2 2017 • Phase I results in Japanese subjects in H2 2017 • 2018: anticipated first launch in Europe and BLA submission in USA • 2019: anticipated launch in USA • Forecast peak sales of >€400M1 • Ablynx to lead commercialisation in USA, Canada and Europe • Orphan Drug Status (EU/USA) – IP protection to 2035 aTTP: acquired thrombotic thrombocytopenic purpura 1 USA, Canada, EU and Japan 14 Caplacizumab unique mode of action Rapidly stops formation of microclots Caplacizumab blocks the platelet – ULvWF interaction
Load more

Recommended publications
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch Et Al
    US010471211B2 United States Patent (10 ) Patent No.: US 10,471,211 B2 Rusch et al. (45 ) Date of Patent: Nov. 12 , 2019 ( 54 ) MEDICAL DELIVERY DEVICE WITH A61M 2005/31506 ; A61M 2205/0216 ; LAMINATED STOPPER A61M 2205/0222 ; A61M 2205/0238 ; A61L 31/048 ( 71 ) Applicant: W.L. Gore & Associates, Inc., Newark , See application file for complete search history. DE (US ) ( 56 ) References Cited ( 72 ) Inventors : Greg Rusch , Newark , DE (US ) ; Robert C. Basham , Forest Hill , MD U.S. PATENT DOCUMENTS (US ) 5,374,473 A 12/1994 Knox et al . 5,708,044 A 1/1998 Branca ( 73 ) Assignee : W. L. Gore & Associates, Inc., 5,792,525 A 8/1998 Fuhr et al. Newark , DE (US ) ( Continued ) ( * ) Notice: Subject to any disclaimer , the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154 (b ) by 0 days . WO WO2014 / 196057 12/2014 WO WO2015 /016170 2/2015 ( 21) Appl. No .: 15 /404,892 OTHER PUBLICATIONS ( 22 ) Filed : Jan. 12 , 2017 International Search Report PCT/ US2017 /013297 dated May 16 , (65 ) Prior Publication Data 2017 . US 2017/0203043 A1 Jul. 20 , 2017 Primary Examiner Lauren P Farrar Related U.S. Application Data ( 74 ) Attorney , Agent, or Firm — Amy L. Miller (60 ) Provisional application No.62 / 279,553, filed on Jan. ( 57 ) ABSTRACT 15 , 2016 . The present disclosure relates to a medical delivery device that includes a barrel having an inner surface , a plunger rod ( 51 ) Int. Cl. having a distal end inserted within the barrel , and a stopper A61M 5/315 ( 2006.01) attached to the distal end of the plunger rod and contacting A61L 31/04 ( 2006.01) at least a portion of the inner surface of the barrel .
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm Laura Runkel Associate Director, Autoimmune/ Inflammation, CNS, Ophthalmology
    Rheumatoid Arthritis: Old and New Approaches Shifting the Treatment Paradigm Laura Runkel Associate Director, Autoimmune/ Inflammation, CNS, Ophthalmology Introduction Rheumatoid arthritis (RA) is a chronic disease next-line biologics. More recently, in 2012, a new that causes progressive articular damage and oral therapy, Pfizer’s Janus protein kinase (JAK) results in a wide range of systemic symptoms 1/3 inhibitor Xeljanz, was approved, opening the due to the associated inflammation. Treatment door to a novel therapeutic approach. Despite paradigms are well established for RA. Methotrexate, the many approved RA therapeutics, at least one a conventional synthetic disease-modifying third of patients remain, or become, unresponsive antirheumatic drug (csDMARD), is the first-line to treatment2. Because of this continued unmet therapeutic in the US, Japan, and five major EU need, and the growing prevalence of RA in an aging markets (France, Germany, Italy, Spain, and the population, industry interest in RA drug development UK)1. Further lines of approved therapeutics are remains high. This analysis, using Trialtrove clinical prescribed to DMARD-resistant patients, with the data, explores the recent clinical landscape, with an anti-TNFs being the major class of biologics in eye towards highlighting programs seeking durable this space. Other approved biologics (Actemra, treatment paradigms, and assessing where the Orencia, and Rituxan) that target different immune market is heading. regulatory pathways are generally prescribed as 1. Datamonitor Healthcare’s Treatment: Rheumatoid Arthritis, February 2017. 2. Hyrich KL, Lunt M, et al. (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    [Show full text]
  • Impact Education RA Symposium.Pdf
    Educational Objectives • Assess decision support tools to enhance medical and pharmacy benefit design decision-making for patients with RA • Interpret results of decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA • Employ specialty pharmacy and disease management services that can improve the quality of care for patients with RA • Provide accurate and appropriate counsel as part of the managed care treatment team Assessing the Clinical Benefits of Rheumatoid Arthritis Therapies in a Managed Care Setting Robin K. Dore, MD Clinical Professor UCLA David Geffen School of Medicine Los Angeles, CA Learning Objective • Review the clinical benefits of early and aggressive treatment of rheumatoid arthritis (RA) RA Treatment Challenges • Complex, multifactorial Progression of RA pathogenesis Disability • Fluctuating clinical course; Inflammation unpredictable prognosis Joint damage • Characterized by units) • Progressive joint destruction Severity (arbitrary • Loss of physical function 0 5 10 15 20 25 30 Years of disease • Poor quality of life • Inflammatory joint symptoms determine disability early in natural history of the disease • Joint destruction dominates disability late in disease Adapted from Kirwan JR. J Rheumatol. 2001;28:881-886. RA Therapeutic Objectives Prevention/ Sustained arrest of remission joint damage Remission Prevention/ Prevention of reversal of systemic disability comorbidities Smolen JS, et al. Ann Rheum Dis. 2010;69:631-637. RA Treatment Strategy Early and Treat-to-Target Achieve Tight Intensive Achieve remission with Control Treatment minimal/no signs or Maintain remission or a Attenuate inflammation symptoms of active low level of disease quickly inflammation activity over time Smolen JS, et al. Ann Rheum Dis.
    [Show full text]
  • (INN) for Biological and Biotechnological Substances
    WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 WHO/EMP/RHT/TSN/2019.1 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) 2019 International Nonproprietary Names (INN) Programme Technologies Standards and Norms (TSN) Regulation of Medicines and other Health Technologies (RHT) Essential Medicines and Health Products (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) FORMER DOCUMENT NUMBER: INN Working Document 05.179 © World Health Organization 2019 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • BMS Scoops Cormorant in $520M Immuno-Oncology Deal
    GSK Gets Digital In Respiratory Is Pharma Geared For Big Efficiency Stockwatch In the latest installment of our Pay-Offs? As Brexit-induced volatility continued executive profile series, GSK’s SVP Eric Driving operational efficiencies may to reverberate across the stock market, Dube explains his expectations for not seem exciting in an industry racing investment bank analysts started to GSK’s future working with technology towards cures for cancer but some data downgrade companies (p21) & digital partners (p3) reveals why drab may be fab (p19) 15 July 2016 No. 3811 Scripscripintelligence.com Pharma intelligence | informa “We believe combination therapy will be foundational to delivering the poten- tial for long-term survival for patients, and the opportunity to develop the HuMax-IL8 antibody program together with our broad immuno-oncology pipeline enables us to accelerate the next wave of potentially transformational immunotherapies,” said Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb. Based on the nature of the molecule and the research phase it is in, analysts at Biomedtracker estimate that HuMax- IL8 currently has a likelihood of approval rating of 6%. Interleukin-8 was first characterized in Maarten de Château, CEO of Cormorant 1987 as a monocyte-derived neutrophil Pharmaceuticals chemotactic factor belonging to the CXC Shutterstock: Cormorant Pharmaceuticals AB Pharmaceuticals Cormorant Shutterstock: chemokine family. It is released from a variety of cells upon stimulation with IL-1, LPS, tumor necrosis factor alpha, viruses BMS Scoops Cormorant In $520M and lectins, and binds to two distinct, G- protein-coupled receptors (GPCRs) CXCR1 and CXCR2. Immuno-Oncology Deal While a number of IL-8 focused mol- MIKE WARD [email protected] ecules have been developed as candidate treatments of inflammatory diseases, BMS Bristol-Myers Squibb Co.
    [Show full text]
  • Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab
    Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Anti-IL6R: Tocilizumab, Satralizumab, Sarilumab, Olokizumab, Vobarilizumab Anti-IL6: Siltuximab, Sirukumab, Clazakizumab Evidence Summary Beneficial for peripheral inflammatory conditions driven by IL-6 mediated pathology, but not well-suited for CNS compartmentalized inflammation, and suppress the immune system’s ability to fight pathogens. Neuroprotective Benefit: Can only reduce IL-6 mediated inflammation in the CNS if the BBB is disrupted. Effects of IL-6 in CNS are context dependent, so blocking IL-6 could improve or impair cognition in different patient populations. Aging and related health concerns: Mixed effects on cardiovascular health by raising LDL-c, while reducing Lp(a) and improving the function of HDL-c. May protect against IL-6 mediated heart damage, but have no clear benefit in cancer. Safety: Suppress immune system and pose risks for undetected infections that can become serious. Reduce
    [Show full text]
  • WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT (51) International Patent Classification: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 38/16 (2006.01) A61K 39/395 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 39/00 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US20 16/042074 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (22) International Filing Date: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 13 July 2016 (13.07.2016) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (30) Priority Data: TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 62/192,269 14 July 2015 (14.07.2015) US TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/197,966 28 July 2015 (28.07.2015) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/277,201 11 January 2016 ( 11.01.2016) u s LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: IMMUNEXT, INC.
    [Show full text]
  • Table of Contents Protocol Amendment Summary of Changes
    Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Clinical Trial Protocol Clinical Trial Protocol Number MS200527-0060 Title A Phase IIb, Randomized, Double-blind Study in Subjects with Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared with Placebo in Subjects with an Inadequate Response to Methotrexate Phase IIb IND Number CCI EudraCT Number 2017-000384-32 Coordinating Investigator PPD Sponsor For all countries except the USA and Japan: Merck KGaA, Frankfurter Str. 250 64293 Darmstadt, Germany For Japan only: Merck Serono Co., Ltd. (Affiliate of Merck KGaA, Darmstadt, Germany) Arco Tower, 1-8-1 Shimomeguro Meguro-ku, Tokyo 153-8926, Japan And For the USA EMD Serono Research & Development Institute, Inc. 45A Middlesex Turnpike Billerica, MA 01821 USA Medical Responsible: PPD EMD Serono Research & Development Institute 45A Middlesex Turnpike, Billerica, MA 01821, USA Telephone: PPD 'RFXPHQW1RCCI 1/130 2EMHFW1RCCI Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Clinical Trial Protocol Version 12 July 2018/Version 3.0 (Amendment 4) Replaces Version 13 December 2017/Version 2.0 'RFXPHQW1RCCI 2/130 2EMHFW1RCCI Evobrutinib Phase IIb in Rheumatoid Arthritis MS200527-0060 Protocol Amendment Summary of Changes Protocol History Version Number Type Version Date 1.0 Original Protocol 11 May 2017 1.1 Amendment specific for US 03 July 2017 2.0 Global Amendment 13 December 2017 2.1 Amendment specific for US 16 November 2017 3.0 Global Amendment 12 July 2018 Protocol Version [3.0] (12-July-2018) This amendment is nonsubstantial based on the criteria in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union because it neither significantly impacts the safety or physical/mental integrity of participants nor the scientific value of the study.
    [Show full text]
  • A61K9/51 (2006.01) — with International Search Report (Art
    ) ( 2 (51) International Patent Classification: Published: A61K9/51 (2006.01) — with international search report (Art. 21(3)) (21) International Application Number: — before the expiration of the time limit for amending the PCT/US20 19/033 875 claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (22) International Filing Date: 24 May 2019 (24.05.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/676,169 24 May 2018 (24.05.2018) US (71) Applicant: ELEKTROFI, INC. [US/US]; 75 Kneeland Street, 14th Floor, Boston, MA 021 11 (US). (72) Inventors: COFFMAN, Chase; 86 Worcester Street, Unit 3, Boston, MA 021 18 (US). CHARLES, Lyndon; 600 Main St Apt 3, Medford, MA 02155 (US). BROWN, Paul; 156 W 6th St, Unit 2, Boston, MA 02127 (US). DADON, Daniel, Benjamin; 2 Garden Court, Apt. 1, Cambridge, MA 02138 (US). LIU, Lisa; 111 Bartlett Street, Apt 2, Somerville, MA 02145 (US). SHADBAR, Sadiqua; 1307 Commonwealth Avenue, Apt 9, Allston, MA 02135 (US). SUDRIK, Chaitanya; 7 1 Elm Street, Apartment #2, Cam¬ bridge, MA 02139 (US). (74) Agent: BELLIVEAU, Michael J. et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 021 10 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Journal for Immunotherapy of Cancer (JITC) Preprint
    Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint is the author/funder, who has granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission. Until the paper has been able to undergo proper copyediting, typesetting, and author proofing, readers should be aware that the specific preprint information below may contain errors and has not been finalized by authors. The Society for Immunotherapy of Cancer Perspective on Regulation of Interleukin 6 Signaling in COVID-19 – related Systemic Inflammatory Response Fernanda I. Arnaldez, Steven J. O’Day, Charles G. Drake, Bernard A. Fox, Binqinq Fu, Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, Paolo A. Ascierto* Keywords: Immunomodulation, Inflammation mediators Fernanda I. Arnaldez, MD: Executive Medical Director, Clinical Development, MacroGenics, Inc., Maryland, USA Steven J. O’Day, MD: Executive Director, John Wayne Cancer Institute and Cancer Clinic Providence Saint John’s Health Center; Regional Director Research, Providence Los Angeles Metro Hospitals, Santa Monica, CA Charles G. Drake, MD, PhD: Director Genitourinary Oncology, Co-Director Immunotherapy, Associate Director for Clinical Research Herbert Irving Cancer Center, NYP/Columbia University Medical Center, New York, USA Bernard A. Fox, PhD: Harder Family Chair for Cancer Research, Earle A. Chiles Research Institute, Providence Cancer Institute, Oregon, USA Binqing Fu, PhD: Professor, School of Life Sciences, University of Science & Technology of China, Hefei City, China Walter J. Urba, MD, PhD: Director, Cancer Research, Earle A. Chiles Research Institute, Providence Cancer Institute, Oregon, USA Vincenzo Montesarchio: Director of Oncology Unit, A.O.R.N.
    [Show full text]